04Jul 2016
MPubmed

Bone. 2016 Jul;88:1-12. doi: 10.1016/j.bone.2016.04.013. Epub 2016 Apr 19.

Overall, our findings suggest the possibility to use early-passage PDPCs for bone regenerative approaches based on the local recruitment of stem cells, whilst the later cell passages could be a suitable in vitro tool to validate scaffolds intended for bone regeneration in elderly subjects.

Autor: Vozzi G, Lucarini G, Dicarlo M, Andreoni C, Salvolini E, Ferretti C, Mattioli-Belmonte M.
04Jul 2016
bone logo

Bone. 2016 Jul;88:125-30. doi: 10.1016/j.bone.2016.04.020. Epub 2016 Apr 22.

In conclusion, the poor healing capacity of incomplete atypical femoral fractures can be explained by biomechanical factors, and daily low impact activities are enough to cause strain magnitudes that prohibit bone formation.

Autor: Gustafsson A, Schilcher J, Grassi L, Aspenberg P, Isaksson H.
04Jul 2016
Springer

Osteoporos Int. 2016 Jul;27(7):2147-79. doi: 10.1007/s00198-016-3515-9. Epub 2016 Apr 28. Review.

The scope of this article is to review the manifestations of and risk factors for primary and secondary osteoporosis in children, to discuss the definition of pediatric osteoporosis, and to summarize recommendations for monitoring and prevention of bone fragility. As well, this article reviews when a child is a candidate for osteoporosis therapy, which agents and doses should be prescribed, the duration of therapy, how the response to therapy is adjudicated, and the short- and long-term side effects. With this information, the bone health clinician will be poised to diagnose osteoporosis in children and to identify when children need osteoporosis therapy and the clinical outcomes that gauge efficacy and safety of treatment.

Autor: Ward LM, Konji VN, Ma J.
04Jul 2016
bone logo

Bone. 2016 Jul;88:125-30. doi: 10.1016/j.bone.2016.04.020. Epub 2016 Apr 22.

In conclusion, the poor healing capacity of incomplete atypical femoral fractures can be explained by biomechanical factors, and daily low impact activities are enough to cause strain magnitudes that prohibit bone formation.

Autor: Gustafsson A, Schilcher J, Grassi L, Aspenberg P, Isaksson H.
04Jul 2016
jama

JAMA Psychiatry. 2016 Jul 20. doi: 10.1001/jamapsychiatry.2016.1383. [Epub ahead of print]

Raloxifene hydrochloride, 120 mg/d, reduces illness severity and increases the probability of a clinical response in women with refractory schizophrenia. This large trial of raloxifene in this patient population offers a promising, well-tolerated agent that has potential application in clinical practice.

Autor: Kulkarni J, Gavrilidis E, Gwini SM, Worsley R, Grigg J, Warren A, Gurvich C, Gilbert H, Berk M, Davis SR
04Jul 2016
wiley-logo

J Bone Miner Res. 2016 Jul;31(7):1429-39. doi: 10.1002/jbmr.2804. Epub 2016 Mar 8.

This study demonstrates for the first time that bone formation indices are higher with TPTD treatment than with ZOL in all four bone envelopes and the difference persists for at least 2 years. Moreover, the magnitude of the effect of TPTD in cortical bone remains robust at 24 months.

Autor: Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao SD, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Alam J, Ruff VA, Gallagher ER, Taylor KA
04Jul 2016
endocrine society

J Clin Endocrinol Metab. 2016 Jul;101(7):2742-50. doi: 10.1210/jc.2015-4135. Epub 2016 May 4.

CONCLUSIONS: Long-term, continuous therapy of hypoparathyroidism for 6 years with rhPTH(1-84) is associated with reductions in supplemental calcium and calcitriol requirements, stable serum calcium concentration, and reduced urinary calcium excretion. The safety profile remains good. These data represent the longest experience with the therapeutic use of PTH for any condition and demonstrate its long-term efficacy and safety in hypoparathyroidism.

Autor: Rubin MR, Cusano NE, Fan WW, Delgado Y, Zhang C, Costa AG, Cremers S, Dworakowski E, Bilezikian JP.
04Jul 2016
endocrine society

J Clin Endocrinol Metab. 2016 Jul;101(7):2728-32. doi: 10.1210/jc.2016-1513. Epub 2016 Apr 12.

CONCLUSIONS: DXA at 3 sites revealed OP at the forearm, but not at the other sites, in 11.2% of aPHPT patients. Half of these cases met surgical criteria based on this one factor alone. These patients did not show any clinical (except age) or biochemical differences from the other patients. The implementation of forearm DXA increases the rate of patients with aPHPT meeting surgical criteria.

Autor: Castellano E, Attanasio R, Gianotti L, Cesario F, Tassone F, Borretta G.
04Jun 2016
wiley-logo

J Bone Miner Res June; 31(6):1167-1176 . doi: 10.1002/jbmr.2797. Epub 2016 Jan 28.

In conclusion, our identification of a novel germline gain-of-function Gα11 mutation, Val340Met, causing ADH2 demonstrates the importance of the Gα11 C-terminal region for G-protein function and CaSR signal transduction.

Autor: Piret SE, Gorvin CM, Pagnamenta AT, Howles SA, Cranston T, Rust N, Nesbit MA, Glaser B, Taylor JC, Buchs AE, Hannan FM, Thakker RV.
04Jun 2016
Springer

Calcif Tissue Int. 2016 Jun;98(6):546-55. doi: 10.1007/s00223-015-0105-3. Epub 2016 Jan 9.
The variability in values generated from Biomedica, R&D Systems and TECOmedical assays raises questions regarding the accuracy and specificity of the assays. Direct comparison of studies using different kits is not possible and great care should be given to measurement of sclerostin, with traceability of reagents. Standardization with appropriate material is required before different sclerostin assays can be introduced in clinical practice.

Autor: Piec I, Washbourne C, Tang J, Fisher E, Greeves J, Jackson S, Fraser WD.